drugset / Trial / NCT02025998
Development of Ibudilast for Alcohol Use Disorder
Phase 1
Completed
24 enrolled
University of California, Los Angeles
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedCrossoverTriple-blindTreatment
Summary
The objective of this proposal is to advance medication development for alcoholism by conducting a safety and initial efficacy study of ibudilast, a neuroimmune modulator and phosphodiesterase inhibitor, for alcohol use disorders.
Timeline
- Start
- 2013-12
- Primary completion
- 2015-06
- Completion
- 2015-06
Publications
- Meredith LR, Green R, Grodin EN, Chorpita M, Miotto K, Ray LA. Ibudilast moderates the effect of mood on alcohol craving during stress exposure. Exp Clin Psychopharmacol. 2022 Oct;30(5):620-631. doi: 10.1037/pha0000458. Epub 2021 Apr 22.
- Cummings JR, Tomiyama AJ, Ray LA. Does the Neuroimmune Modulator Ibudilast Alter Food Craving? Results in a Sample With Alcohol Use Disorder. J Addict Med. 2018 Sep/Oct;12(5):410-417. doi: 10.1097/ADM.0000000000000416.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibudilast | Small molecule | 50 mg | — |